A handheld breath analyzer developed at ETH Zurich can tell whether your body is actively burning fat, reading the signal from a single exhale. The device measures acetone — a volatile byproduct of fatty acid breakdown — and came close to the accuracy of laboratory-grade mass spectrometry in a small trial, according to a study published on July 22 in the journal Device.
The pitch is simple. Blow into a small tube, get a real-time readout of whether you’re in ketosis, skip the finger-prick blood test and the weeks of waiting for a bathroom scale to nudge downward.
Whether that pitch survives contact with a larger patient population is another question.
What acetone reveals about metabolism
When the body runs low on glucose — during fasting, low-carb eating, or sustained exercise — it starts breaking down fatty acids for fuel. That process generates ketone bodies, one of which is acetone. Some of that acetone diffuses out of the bloodstream into the lungs and leaves the body in breath.
The concentration is tiny, measured in parts per million or less, which is why clinical labs have historically relied on blood draws or specialized equipment to track ketosis reliably.
Blood ketone levels can be read with a finger-prick test, but that is invasive and impractical for frequent monitoring. Andreas Güntner, professor of molecular sensing at ETH Zurich and the study’s senior author, has spent more than a decade developing gas sensors sensitive enough to read acetone directly from breath as a less painful alternative.
Breath, in other words, is the less painful window into the same biochemistry.
How the device works
The Zurich team’s sensor sits inside a handheld unit paired with a smartphone app. The app coaches the user through a controlled exhalation — flow rate and duration matter, because breath composition changes depending on how deeply and slowly a person breathes.
Inside the device, a catalytic filter and a separation stage isolate acetone from the rest of the exhaled mixture — water vapor, carbon dioxide, ethanol, and hundreds of other trace volatiles — before it reaches the sensor. Selectivity is the hard part in breath analysis. Consumer ketone breath gadgets have often been criticized for cross-reacting with unrelated compounds and drifting out of calibration.
The prototype has been commercialized as Nutrion by Alivion AG, a spin-off from ETH Zurich in which Güntner and co-author Jan van den Broek hold shares. ETH Zurich holds the patent for the underlying technology.
The validation, and its limits
The team tested the device on 12 healthy adults, running them through exercise and dietary changes — light and intense exercise, a high-fat ketogenic meal, and fasting — designed to push them into and out of fat-burning states. Across 312 breath samples spanning acetone concentrations from 0.2 to 45 parts per million, the handheld readings were compared against proton transfer reaction time-of-flight mass spectrometry, or PTR-MS, the reference standard for trace gas analysis in exhaled breath.
The two methods showed strong agreement. When both instruments measured the same breath at the same moment, the handheld device’s reading differed from PTR-MS by about 7.5 percent at 2 ppm — precise enough to catch the fine shifts that mark the switch from burning carbohydrates to burning fat.
The sample size is small — the kind of number that establishes proof of concept in a controlled academic setting but doesn’t yet answer questions that matter for real-world use: how the device performs across ages, body compositions, disease states, medications, and dietary patterns. It also doesn’t establish how it holds up in the humid, variable conditions of a bathroom or a gym. The developers note the device has not yet been validated or approved as a diagnostic tool for clinical use.
Biomarker research has a long history of promising early results that shrink once trials scale up. Analysis in Nature Reviews Drug Discovery has argued that validation across diverse populations, not initial agreement with a lab method, is what ultimately determines whether a marker becomes clinically useful.
Why fat-burning feedback is a big consumer target
The appeal to dieters is obvious. Traditional weight-loss feedback — the scale, the tape measure, the mirror — lags real metabolic change by days or weeks and gets muddled by water retention, glycogen swings, and muscle gain. A device that signals within minutes whether a workout or a meal pushed the body toward fat oxidation offers something closer to instant feedback.
The ketogenic diet community has driven demand for at-home ketone monitoring for years. Blood ketone meters exist but require lancets and strips. Urine strips are cheap but crude, and they lose accuracy as the body adapts to sustained ketosis.
Breath sits between those approaches. It’s non-invasive like urine testing but potentially as accurate as blood — if the sensor chemistry holds up.
The clinical angle beyond weight loss
Ketosis matters medically as well as cosmetically. People with type 1 diabetes can slip into diabetic ketoacidosis, a life-threatening condition, when insulin runs low and ketones flood the bloodstream. Rapid, painless breath monitoring could in principle help patients catch dangerous ketone rises earlier than blood testing typically allows.
Ketogenic diets are also prescribed clinically for drug-resistant epilepsy, particularly in children, where diet compliance is currently awkward to track. The ETH team is working with the University Children’s Hospital Zurich to test whether the handheld device can help children on ketogenic therapy monitor their metabolic state more easily. Metabolic researchers studying obesity, fasting, and exercise physiology would also benefit from a way to sample ketone kinetics more frequently than discrete blood draws allow.
None of that comes without regulatory hurdles. A device sold purely as a wellness tracker faces one set of rules; a device marketed for diabetes management or epilepsy monitoring faces a much steeper approval path. In the United States, the FDA is seeking public input on how it should treat non-device software and other adjacent health technologies, part of a broader reassessment of where consumer health tools fall on the regulatory map.
What to watch next
The team behind Nutrion has flagged larger validation studies as the next step. Key questions include whether the device’s accuracy holds in people with diabetes, whether it can distinguish exercise-induced ketosis from dietary ketosis, and whether the smartphone-guided breathing protocol works reliably outside supervised research settings.
The distance between a small academic trial and a shelf at a pharmacy is longer than it looks. Consumer breath alcohol testing took decades to become reliable enough for legal use, and ketone breath analysis is arguably a harder analytical problem because the target concentrations are lower and the interfering compounds are more numerous.
For now, the ETH Zurich work establishes something narrower but still meaningful: a handheld sensor can, under controlled conditions, track fat metabolism in real time with accuracy that comes close to a laboratory instrument. The rest is engineering, epidemiology, and paperwork.